The Polish Lymphoma Research Group (PLRG) is an association of specialists involved in the treatment of patients with lymphomas of various types, which has been operating since 2008. The year 2023 was a time of change for PLRG. Prof. Jan Maciej Zaucha, MD, head of the Department of Hematology and Transplantology at the Medical University of Gdansk, was appointed president. The Association's logo and website got a new look.
New launch of the Polish Lymphoma Research Group
Published Feb. 22, 2024 09:59
The new logotype consists of acronyms derived from the name "Polish Lymphoma Research Group," arranged in the form of a signet ring. The rounded form is intended to allude to elements such as lymph nodes and the structure of lymphocytes. The choice of red and white colors indicates the Group's place of origin and its medical nature.
At www.plrg.pl provides information about the Association: its goals, the composition of the Board of Directors and the working groups operating within the PLRG. The site also features the latest reports related to the Group's activities and information on planned events.
The main, goal of the members of the Polish Lymphoma Research Group is to conduct clinical trials to improve the outcome of lymphoma patients. In addition to this, PLRG members are involved in activities aimed at optimizing the diagnosis of lymphoma and the treatment of lymphoma patients, in particular by developing recommendations for the diagnosis and treatment of lymphoma, and exchanging experiences between centers at home and abroad, as well as providing information and conducting educational events, including workshops and conferences, aimed at both patients and the medical community.
According to Prof. Jan Maciej Zaucha, president of the Polish Lymphoma Research Group, "In relation to solid tumors, the treatment results are better, more patients can be cured. However, our dream is to cure every patient, hence sometimes even a small percentage of refractory or recurrent patients is a problem for us. There is certainly still a lot of work to be done. Lymphomas are very diverse; for Hodgkin's lymphoma, standard treatment is relatively effective. On the other hand, there are T-cell lymphomas for which we do not yet have a good treatment, or some highly aggressive B-cell lymphomas, with negative prognostic factors, where even intensive treatment does not always lead to a cure, and sometimes the only chance is to use innovative therapies, such as CAR-T , bispecific antibodies or allogeneic hematopoietic cell transplantation."
Among the educational activities organized by the Association is a unique workshop scheduled for March 15, 2024 in Warsaw, designed for doctors interested in good treatment of lymphoma patients, which will precede the Plenary Meeting of the Polish Lymphoma Study Group on March 14. Workshop participants have the chance to meet with top Polish experts in small study groups discussing the hottest topics and controversies in lymphoma treatment including their "difficult" patients
I attach graphics for your use:
For more information, visit:
Source: press mat.
